IVIXF (Invion) Beginning Cash Position: $0.57 Mil (As of Dec. 2025)


IVIXF Invion Ltd IVIXF
16 GF Score
Price $0.04
GF Value $0.21
! 1 Warning Sign
View Full Analysis

What is Invion Beginning Cash Position?

Invion IVIXF -83.23% 16 Beginning Cash Position is $0.57 Mil as of Dec. 2025. GuruFocus rates IVIXF with a GF Score™ of 16/100 and a GF Value™ of $0.21. The stock has 1 warning sign investors should review.

Invion's Beginning Cash Position for the quarter that ended in Dec. 2025 was $0.57 Mil.

Invion's quarterly Beginning Cash Position declined from Dec. 2024 ($0.50 Mil) to Jun. 2025 ($0.48 Mil) but then increased from Jun. 2025 ($0.48 Mil) to Dec. 2025 ($0.57 Mil).

Invion's annual Beginning Cash Position declined from Jun. 2023 ($5.69 Mil) to Jun. 2024 ($2.71 Mil) and declined from Jun. 2024 ($2.71 Mil) to Jun. 2025 ($0.51 Mil).

Invion Beginning Cash Position Related Terms

Invion Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Invion's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invion Beginning Cash Position Chart

Invion Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.47 0.73 5.69 2.71 0.51

Invion Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.73 1.29 0.50 0.48 0.57
IVIXF
16GF Score
Invion Ltd IVIXF
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Invion Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $0.57 Mil mean?
Invion (IVIXF) has a Beginning Cash Position of $0.57 Mil as of Dec. 2025. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Invion and its competitors.
Is Invion's Beginning Cash Position too high?
Invion's current Beginning Cash Position is $0.57 Mil. Overall, Invion has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Invion's Beginning Cash Position compare to ZTS and UTHR?
Invion's Beginning Cash Position of $0.57 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Drug Manufacturers company?
A good Beginning Cash Position depends on the Drug Manufacturers industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Invion and its competitors. Invion's current Beginning Cash Position is $0.57 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invion stock overvalued right now?
Invion (IVIXF) has a current Beginning Cash Position of $0.57 Mil. The stock's GF Value™ is $0.21, compared to a current price of $0.04 — trading 82.4% below its estimated fair value. The current Beginning Cash Position is $0.57 Mil. Invion's overall GF Score™ is 16/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Invion (IVIXF), the current Beginning Cash Position is $0.57 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Invion (IVIXF) Overvalued in 2026?

Based on GuruFocus' analysis, Invion stock appears to be undervalued. The current stock price of $0.04 is trading 82.4% below its estimated GF Value™ of $0.21.

Key valuation signals for IVIXF:

  • Beginning Cash Position: $0.57 Mil
  • GF Value™: $0.21 vs. price of $0.04 (82.4% below fair value)
  • GF Score™: 16/100 with 1 warning sign

No single metric tells the full story. See the IVIXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Invion Business Description

Other Exchanges 7C8:GermanyIVX:Australia
Address 692 High Street, East Kew, VIC, AUS, 3102
Invion Ltd is an Australian clinical-stage pharmaceutical drug development company. It is engaged in the development of PhotoDynamic Therapy (PDT) for cancer treatments called Photosoft, for the treatment of a range of cancers, and infectious diseases. The company produces topical and intravenous products suitable for use in skin cancer and solid tumors, such as ovarian, prostate, and lung cancer. Invion has developed a portfolio of patent protected compounds. Its drug candidate is INV043, a novel photosensitiser which has the potential to work as a therapy and a diagnostic tool.
16GF Score

Get the complete analysis for IVIXF

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.04
Price
$0.21
GF Value